References
- Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010:287–294.
- Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319–328.
- Cohen AD, Zhou P, Xiao Q, et al. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. Br J Haematol 2004;124:309–314.
- Dou X, Hu H, Ju Y, et al. Concurrent nephrotic syndrome and acute renal failure caused by chronic lymphocytic leukemia (CLL): a case report and literature review. Diagn Pathol 2011;6:99.
- Ikee R, Kobayashi S, Hemmi N, et al. Amyloidosis associated with chronic lymphocytic leukemia. Amyloid 2005;12:131–134.
- Sanchorawala V, Blanchard E, Seldin DC, et al. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol 2006;81:692–695.
- Bernstein ZP, Fitzpatrick JE, O’Donnell A, et al. Clinical significance of monoclonal proteins in chronic lymphocytic leukemia. Leukemia 1992;6:1243–1245.
- Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 2011;118:2821–2826.
- Pratt G, Harding S, Holder R, et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol 2009;144:217–222.
- Yegin ZA, Ozkurt ZN, Yağci M. Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia. Eur J Haematol 2010;84:406–411.
- Telio D, Bailey D, Chen C, et al. Two distinct syndromes of lymphoma associated AL amyloidosis: a case series and review of the literature. Am J Hematol 2010;85:805–808.
- Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010;85:232–238.
- Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
- Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.